
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Agomelatine Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seaport Therapeutics Doses First Participant in Phase 1 of GlyphAgo (SPT-320)
Details : Agomelatine's mechanism of action involves its actions as a melatonin receptor agonist and a 5-HT2C receptor antagonist, which increase dopamine and norepinephrine in pateints with GAD.
Product Name : SPT-320
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : Agomelatine Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glyph Allopregnanolone is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2025
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SPT-300
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
SPT-300 (GlyphAllo) Safety & Efficacy In Major Depressive Disorder ± Anxious Distress
Details : SPT-300 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2025
Lead Product(s) : SPT-300
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : General Atlantic
Deal Size : $225.0 million
Deal Type : Series B Financing
Seaport Therapeutics Closes $225M Series B Financing Round
Details : Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines, including SPT-300 (glyph allopregnanolone), an oral prodrug of allopregnanolone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2024
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : General Atlantic
Deal Size : $225.0 million
Deal Type : Series B Financing

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials
Details : SPT-300 (glyph-allopregnanolone), an oral prodrug of allopregnanolone, an endogenous neurosteroid, a GABAA PAM, is in clinical stage development for the treatment of mood and anxiety disorders
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All